Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies

NCT03030001 is registered in ClinicalTrials.gov with Ningbo Cancer Hospital as lead sponsor.

NCT NCT03030001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03030001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies
Lead sponsor
Ningbo Cancer Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 15, 2017
Completion date
February 1, 2019
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, solid tumor, adult